Instituut voor Neuropathische Pijn

In an abstract presented at the American Academy of Pain Medicine meeting in San Antonio it was suggested that an extended-release oxymorphone (brand name: Opana) could be a reasonable treatment option for cancer patients needing long-term neuropathic pain management.

The press release was based on a small study, sponsored by Endo Pharmaceuticals (owners of Opana) and the claim was that extended-release oxymorphone may be of some benefit for patients suffering from chronic neuropathic pain in cancer.

Further details were not given and we need the full data to able to understand whether indeed this formulation might be of some benefit.

Source: Slatkin N, et al. Long-term management of neuropathic cancer pain with oxymorphone extended release: Results of a 1-year open-label extension trial AAPM 2010; Abstract 117.

Februari 2010, Jan M. Keppel Hesselink, MD, PhD